Improvement of antibody functionality by structure-guided paratope engraftment

被引:0
作者
Qingbo Liu
Yen-Ting Lai
Peng Zhang
Mark K. Louder
Amarendra Pegu
Reda Rawi
Mangaiarkarasi Asokan
Xuejun Chen
Chen-Hsiang Shen
Gwo-Yu Chuang
Eun Sung Yang
Huiyi Miao
Yuge Wang
Anthony S. Fauci
Peter D. Kwong
John R. Mascola
Paolo Lusso
机构
[1] National Institute of Allergy and Infectious Diseases,Laboratory of Immunoregulation
[2] NIH,Vaccine Research Center
[3] National Institute of Allergy and Infectious Diseases,undefined
[4] NIH,undefined
来源
Nature Communications | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Broadly neutralizing antibodies (bNAbs) represent a promising alternative to antiretroviral drugs for HIV-1 prevention and treatment. Selected antibodies to the CD4-binding site bolster envelope trimer binding via quaternary contacts. Here, we rationally engraft a new paratope, i.e., the extended heavy-chain framework region 3 (FR3) loop of VRC03, which mediates quaternary interaction, onto several potent bNAbs, enabling them to reach an adjacent gp120 protomer. The interactive quaternary surface is delineated by solving the crystal structure of two FR3 loop-chimeric antibodies. Chimerization enhances the neutralizing activity of several potent bNAbs against a majority of global HIV-1 strains. Compared to unmodified antibodies, chimeric antibodies display lower autoreactivity and prolonged in vivo half-life in huFcRn mice and rhesus macaques. Thus, paratope engraftment may be used to expand the epitope repertory of natural antibodies, improving their functionality for disease prevention and treatment.
引用
收藏
相关论文
共 59 条
[1]  
Burton DR(2012)Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses Science 337 183-186
[2]  
Poignard P(2014)Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface Nature 515 138-142
[3]  
Stanfield RL(2013)Antibodies in HIV-1 vaccine development and therapy Science 341 1199-1204
[4]  
Wilson IA(2012)Immune-correlates analysis of an HIV-1 vaccine efficacy trial N. Engl. J. Med. 366 1275-1286
[5]  
Huang J(2016)Lessons from HIV-1 vaccine efficacy trials Curr. Opin. HIV AIDS 11 607-613
[6]  
Klein F(2013)HIV-1 neutralizing antibodies: understanding nature’s pathways Immunol. Rev. 254 225-244
[7]  
Haynes BF(2012)HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins J. Virol. 86 11231-11241
[8]  
Excler JL(2014)Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies J. Virol. 88 2489-2507
[9]  
Michael NL(2017)A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure Immunity 46 690-702
[10]  
Mascola JR(2005)Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies Science 308 1906-1908